Creative Medical shares rise 10.64% premarket as Zacks cites shifting bearish sentiment and 'Buy' recommendation.

Creative Medical Technology Holdings, Inc. (CELZ) surged 10.64% in premarket trading, driven by recent bullish developments. The company announced agreements to exercise warrants for $4.2 million in gross proceeds, enhancing liquidity and investor confidence. Additionally, Zacks highlighted a shift in market sentiment, labeling CELZ a "Buy" as bears lose control, citing improved fundamentals. These events align with the stock's upward movement, reflecting optimism over capital raising and strategic positioning. Earlier FDA designations and clinical trial progress for therapies like CELZ-201-DDT also underscore long-term growth potential, though the immediate premarket rally appears most directly linked to the recent funding and analyst upgrade.